{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:59:53Z","timestamp":1787795993107,"version":"build-2784847793"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T00:00:00Z","timestamp":1699056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,16]]},"abstract":"<jats:p>Dystrophic epidermolysis bullosa (DEB) is a rare inherited blistering skin disease that causes lifelong, slow-to-heal wounds, which predispose patients to chronic inflammation, scarring and an increased risk of developing squamous cell carcinoma. Management is largely supportive with no approved corrective therapies currently available. We critically appraise the phase III clinical trial reported by Guide et al., investigating the topical application of beremagene geperpavec on cutaneous wounds in DEB.<\/jats:p>","DOI":"10.1093\/bjd\/ljad433","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T17:32:22Z","timestamp":1698946342000},"page":"340-342","source":"Crossref","is-referenced-by-count":6,"title":["Beremagene geperpavec (B-VEC) gene therapy for the treatment of cutaneous wounds in patients with dystrophic epidermolysis bullosa: a critically appraised research paper"],"prefix":"10.1093","volume":"190","author":[{"given":"Brent J","family":"Doolan","sequence":"first","affiliation":[{"name":"Genetic Skin Disease Group, St John\u2019s Institute of Dermatology, School of Basic and Medical Biosciences, King\u2019s College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3708-9964","authenticated-orcid":false,"given":"John A","family":"McGrath","sequence":"additional","affiliation":[{"name":"Genetic Skin Disease Group, St John\u2019s Institute of Dermatology, School of Basic and Medical Biosciences, King\u2019s College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2670-8117","authenticated-orcid":false,"given":"Jemima\u00a0E","family":"Mellerio","sequence":"additional","affiliation":[{"name":"Genetic Skin Disease Group, St John\u2019s Institute of Dermatology, School of Basic and Medical Biosciences, King\u2019s College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,4]]},"reference":[{"key":"2024122319392926300_ljad433-B1","first-page":"78","article-title":"Epidermolysis bullosa","volume-title":"Nat Rev Dis Primers","author":"Bardhan","year":"2020"},{"key":"2024122319392926300_ljad433-B2","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41591-022-01737-y","article-title":"In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial","volume":"28","author":"Gurevich","year":"2022","journal-title":"Nat Med"},{"key":"2024122319392926300_ljad433-B3","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","article-title":"Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa","volume":"387","author":"Guide","year":"2022","journal-title":"N Engl J Med"},{"key":"2024122319392926300_ljad433-B4","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"152","author":"Schulz","year":"2010","journal-title":"Ann Intern Med"},{"issue":"127","key":"2024122319392926300_ljad433-B5","article-title":"Herpes simplex virus evasion of early host antiviral responses","volume":"9","author":"Tognarelli","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"2024122319392926300_ljad433-B6","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40265-023-01921-5","article-title":"Beremagene geperpavec: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"2024122319392926300_ljad433-B7","author":"US Food and Drug Administration"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad433\/54645917\/ljad433.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/3\/340\/56690253\/ljad433.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/3\/340\/56690253\/ljad433.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T14:39:33Z","timestamp":1734964773000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/3\/340\/7344665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,4]]},"references-count":7,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,11,4]]},"published-print":{"date-parts":[[2024,2,16]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad433","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2023,11,4]]}}}